drugset / Trial / NCT00246025
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
RandomizedParallel-groupDouble-blindPrevention
Summary
The goal of this study is to evaluate the comparative efficacy and safety of three different doses ( 110 mg, 150 mg, 220 mg) of BIBR 1048 (Dabigatran etexilate) orally, compared to placebo, in prevention of venous thromboembolism in patient with primary elective total knee replacement surgery, and to evaluate dose-response.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 110 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 220 mg | Oral |